Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

被引：0

作者：

Jun Guo

Jie Jin

Mototsugu Oya

Hirotsugu Uemura

Shunji Takahashi

Katsunori Tatsugami

Sun Young Rha

Jae-Lyun Lee

Jinsoo Chung

Ho Yeong Lim

Hsi Chin Wu

Yen Hwa Chang

Arun Azad

Ian D. Davis

Marlene J. Carrasco-Alfonso

Bhupinder Nanua

Jackie Han

Qasim Ahmad

Robert Motzer

机构：

[1] Peking University Cancer Hospital and Institute,Department Urology and Melanoma

[2] Peking University First Hospital,Department of Urology

[3] Keio University School of Medicine,Department of Urology

[4] Kindai University Faculty of Medicine,Department of Urology

[5] Cancer Institute Hospital,Department of Medical Oncology

[6] Japanese Foundation for Cancer Research,Department of Urology, Graduate School of Medical Sciences

[7] Kyushu University,Department of Oncology and Internal Medicine, Asan Medical Center

[8] Yonsei Cancer Center,Department of Urology

[9] Yonsei University College of Medicine,Division of Hematology

[10] University of Ulsan College of Medicine,Oncology

[11] Center for Prostate Cancer,Department of Urology

[12] National Cancer Center,Division of Urology, Department of Surgery

[13] Samsung Medical Center,Department of Medicine

[14] Sungkyunkwan University,Department of Medicine

[15] China Medical University Hospital,undefined

[16] Taipei Veterans General Hospital,undefined

[17] Monash University,undefined

[18] Monash University,undefined

[19] Eastern Health Clinical School,undefined

[20] Novartis Pharmaceuticals Corporation,undefined

[21] Novartis Pharmaceuticals Corporation,undefined

[22] Genitourinary Oncology Service,undefined

[23] Memorial Sloan-Kettering Cancer Center,undefined

来源：

Journal of Hematology & Oncology | / 11卷

关键词：

Renal cell carcinoma; Pazopanib; Sunitinib;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma
Santoni, Matteo
Conti, Alessandro
Porta, Camillo
Procopio, Giuseppe
Sternberg, Cora N.
Basso, Umberto
De Giorgi, Ugo
Bracarda, Sergio
Rizzo, Mimma
Ortega, Cinzia
Massari, Francesco
Iacovelli, Roberto
Derosa, Lisa
Masini, Cristina
Milella, Michele
Di Lorenzo, Giuseppe
Atzori, Francesco
Pagano, Maria
Buti, Sebastiano
De Vivo, Rocco
Mosca, Alessandra
Rossi, Marta
Paglino, Chiara
Verzoni, Elena
Cerbone, Linda
Muzzonigro, Giovanni
Falconi, Massimo
Montironi, Rodolfo
Burattini, Luciano
Santini, Daniele
Cascinu, Stefano
JOURNAL OF UROLOGY, 2015, 193 (01): : 41 - 47
[22] Sunitinib versus pazopanib for patients with metastatic renal cell carcinoma: 2 Turkish hospital experience
Ekenel, M.
Karabulut, S.
Cil, I
Zirtiloglu, A.
Aydin, E.
Tural, D.
ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (01): : 27 - 33
[23] CLINICAL OUTCOME OF ASIAN VS. NON-ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WITH CONTINUOUS ONCE-DAILY DOSING OF SUNITINIB AS FIRST-LINE THERAPY
Barrios, C. H.
Hernandez-Barajas, D.
Brown, M. P.
Lee, S.
Fein, L.
Liu, J.
Hariharan, S.
Martell, B.
Yuan, J.
Rha, S. Y.
ANNALS OF ONCOLOGY, 2010, 21 : 286 - 286
[24] Vascular endothelial growth factor (VEGF) therapy in metastatic renal cell carcinoma (mRCC): Differences between Asian and non-Asian patients.
Wang, Ying
Choueiri, Toni K.
Lee, Jae-Lyun
Tan, Min-Han
Rha, Sun Young
North, Scott A.
Kollmannsberger, Christian K.
Heng, Daniel Yick Chin
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
[25] Results of an international Intregroup randomized phase III trial of pazopanib versus placebo (AGO-OVAR16). Subgroup Analysis of toxicity and clinical outcome in the Asian and Non-Asian population
Sehouli, J.
Harter, P.
Wimberger, P.
Rau, J.
Baumann, K.
Kurzeder, C.
Canzler, U.
Meier, W.
Hanker, L. C.
Mahner, S.
Krabisch, P.
Reiter, W. W.
Aminossadati, B.
du Bois, A.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 75 - 75
[26] Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial
Soo, Ross A.
Tan, Eng Huat
Hayashi, Hidetoshi
Seto, Takashi
Lin, Chia-Chi
Ou, Sai-Hong Ignatius
Kim, Dong-Wan
Liu, Geoffrey
Abbattista, Antonello
Martini, Jean-Francois
Martini, Francois
Wong, Chew Hooi
Toffalorio, Francesca
Solomon, Benjamin J.
LUNG CANCER, 2022, 169 : 67 - 76
[27] RECORD-4 multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis
Yang, L.
Alyasova, A.
Ye, D.
Karpenko, A.
Li, H.
Alekseev, B.
Xie, L.
Kurteva, G.
Kowalyszyn, R.
Karyakin, O.
Neron, Y.
Cosgriff, T.
Collins, L.
Brechenmacher, T.
Lin, J.
Morgan, L.
Motzer, R.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S524 - S524
[28] RECORD-4: Multicenter phase 2 trial of second-line everolimus (EVE) in patients (pts) with metastatic renal cell carcinoma (mRCC): Asian versus non-Asian population subanalysis
Yang, L.
Alyasova, A.
Ye, D.
Karpenko, A.
Li, H.
Alekseev, B.
Xie, L.
Kurteva, G.
Kowalyszyn, R. D.
Karyakin, O.
Neron, Y. V.
Cosgriff, T. M.
Collins, L.
Brechenmacher, T.
Lin, J. C.
Morgan, L.
Motzer, R.
ANNALS OF ONCOLOGY, 2015, 26 : 72 - 72
[29] A randomized double-blind cross-over patient preference study of pazopanib versus sunitinib in treatment-naive locally advanced or metastatic renal cell carcinoma (mRCC)
Escudier, B. J.
Cella, D.
Gschwend, J. E.
Powles, T.
Sternberg, C. N.
Hodge, R.
Lau, M.
Neary, M.
Mehmud, F.
Eisen, T.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[30] First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis of data from a phase III trial
Sheng, X.
Bi, F.
Ren, X.
Cheng, Y.
Wang, J.
Rosbrook, B.
Jiang, M.
Guo, J.
ANNALS OF ONCOLOGY, 2017, 28 : 82 - 82

← 1 2 3 4 5 →